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Surgical excision remains the preferred treatment for resectable hepatic metastases of neuroendocrine tumors. In cases of
more disseminated hepatic disease, transarterial radioembolization with Yttrium-90- (90Y-) labeled microspheres has been
demonstrated as a viable option for symptom and locoregional tumor control. On an outpatient basis, radioembolization can
be utilized from early line to salvage phases, in various combinations with systemic therapies. Review of available data shows
encouraging safety and eﬃcacy proﬁles for the intraarterial application of 90Y for the treatment of mNETs of the liver. Symptom
control and decrease in somatostatin analog use can be achieved, as well as prolonged survival.
1.Introduction
Afterremovaloftheprimary,isolatedmetastasesofneuroen-
docrine tumors to the liver can be curatively approached
by surgical resection with achievable disease-free survival
of 42 to 46 months depending on the extent of metastases
[1]. However, only 10% of metastatic liver disease cases
a r er e s e c t a b l e[ 2]. Also, signiﬁcant surgical morbidity and
mortality as well as the unpredictable natural history of
malignant neuroendocrine neoplasms has to be considered
[2]. Consensus guidelines for digestive (neuro)endocrine
tumors currently call for complete hepatic deposit resection
or 90% debulking if feasible [3] since their introduction
in the 1980s somatostatin analogs have signiﬁcantly helped
in symptom control of functional neuroendocrine tumors.
Their eﬀectiveness, however, tends to diminish over time
due to tachyphylaxis and disease progression. An antiprolif-
erative eﬀect has been ascribed to somatostatin analogs on
their own [4]. Additional labeling with radionuclides (e.g.,
177Lutetium-DOTA-TATE) has shown response rates of 13–
30%andmedianoverallsurvivalof13–46monthsalongwith
signiﬁcant clinical beneﬁt [5–10].
Overall, metastatic neuroendocrine tumors have exhib-
ited modest response to systemic chemotherapy. Strep-
tozocin- and doxorubicin-based protocols achieve response
r a t e so fu pt o1 6 % .I nm o r ep o o r l yd i ﬀerentiated NETs a
41.5% response rate has been seen with cisplatin/etoposide
combinations [6–10]. Recently, 70% partial remissions with
estimated overall survival of 92% at 2 years have been re-
ported with a temozolamide/capecitabine regimen in me-
tastatic NET of the pancreas [11].
Novel agents targeting diverse receptors are in various
stages of development. Preliminary data for sunitinib, a mul-
tikinase inhibitor, for example, demonstrate a promising




Retrospective studies have shown beneﬁt to both TAE and
TACE in the treatment of mNET with regard to tumor
growth, symptom control, and biochemical surrogates. In
the most recent large retrospective study of 123 treated
patients undergoing an average of 7 chemoembolization
cycles each, 62% partial response was seen with overall 3-,
5-,and10-yearsurvivalsof59,36,and20%,respectively,and
o v e r a l lm e a ns u r v i v a lo f5 . 4 7y e a r s[ 12].2 International Journal of Hepatology
This result is corroborated by the 67% ORR (mean sur-
vival 33.8 months) in another large study employing TACE
and TAE for the treatment of carcinoid hepatic metastases.
A separate group of islet cell carcinomas in the latter study
exhibited an ORR of only 34% (mean survival 23.2 months);
in the former study 10 cases with insulin/glucagon secretion
were subsumed in the study population [12, 13].
No consensus has been established regarding technique,
embolizing, and chemotherapeutic agents in TACE. Overall,
both TAE and TACE appear to elicit similar responses from
NET liver metastases, suggesting relative primacy of the
embolic eﬀect [2, 14].
3. TransarterialRadiombolization (TARE)
Transarterial radioembolization (TARE) or selective internal
radiotherapy (SIRT) with Yttrium-90 microspheres rep-
resents a further viable option in the treatment arsenal
for nonresectable liver metastases of both functional and
nonfunctional NETs. A number of retrospective as well as
a few prospective studies demonstrate eﬃcacy and safety
combined with the convenience of an outpatient procedure
that rarely requires hospitalization (Table 1)[ 15–25]. What
is more, it appears that the primarily one-time treatments
withTAREcomparefavorablytousuallymultipleprocedures
required TA(C)E regimens.
Two kinds of Yttrium-90 microspheres are currently
approved for treatment of unresectable liver tumors on
the European market: Yttrium-90 resin microspheres (SIR-
spheres; Sirtex Medical, Sydney) with 20–60µm diameter
mounted with a radioactive load of approximately 50Bq per
sphere,aswellas20–30µmglassmicrospheres(TheraSphere,
MDS Nordion, Ottawa) with the higher radioactive load of
2500Bq. SIR-spheres come with premarket approval (PMA)
for unresectable hepatic metastases of colorectal cancer
in the United States and may be utilized “oﬀ-label” for
other tumors without prejudice under the using physicians
discretion authority and responsibility. Therasphere has a
humanitarian device exception for the treatment of hep-
atocellular carcinoma in the US which is more restrictive
than PMA and requires an IRB protocol and limitations to
hepatocellular carcinoma (HCC) only.
A phase II trial of Yttrium-90 resin microspheres in com-
bination with systemic FU chemotherapy was conducted
with 34 patients. While this represented ﬁrst-line therapy for
the majority of patients, 29% had failed prior liver resection
and 15% had received earlier chemotherapy, with 59% also
manifesting extrahepatic disease. Complete response was
eﬀected in 18%, partial response in 32%, and stable disease
15% of cases. Symptom improvement and Chromogranin
A decrease at 6 months were seen in 50% and 41% of
cases, respectively. 59% of patients remained alive at 37 ± 2
months, with 12 patients without hepatic recurrence at 33.3
± 2.3 months [20].
Another prospective trial with Yttrium-90 resin micro-
spheres involved ten patients with progressive or symp-
tomatic unresectable hepatic spread of NET. 40% partial re-
sponse was seen at 6 months and 2 out of 3 patients ex-
perienced symptomatic improvement, and average quality
of life climbed to general-population levels by 6 months.
Seven patients were still alive at 35 months followup, with
the three intervening deaths attributable to progression of
extrahepatic disease. Little toxicity was observed, with the
authors noting comparable to better toleration of TARE
compared to TACE [23].
Another study with Yttrium-90 resin microspheres also
had quality of life as an endpoint and could demonstrate sig-
niﬁcant improvement of quality of life [18].
In a third prospective trial, 20 and 22 patients with
mNET were treated with resin and glass Yttrium-90 micro-
spheres, respectively, after the patient had previously under-
gone surgery (36%), ablation (19%), TA(C)E (14%), and
symptomatic treatment (60%). ORR resulted in 50% and
54%, and stable disease in 44% and 38.5%, respectively.
Projected median survival times were 28 and 22 months,
respectively (not statistically signiﬁcant diﬀerence), with the
majority of patients alive at time of study publication [22].
T h el a r g e s tr e t r o s p e c t i v es t u d yt od a t er e v i e w e dat o t a l
of 148 patients in 10 clinical centers treated with Yttrium-
90 resin microspheres in a primarily salvage setting of
mNET. 70 months median survival with 63% ORR and 23%
stable disease were demonstrated, with most deaths due to
progression of extrahepatic disease. Toxicity was very low,




also performed in a minority of patients in other studies,
with a few receiving a third treatment [19, 20, 24, 25]. No
case of RILD was seen and an increased duration of tumor
response in cases of hepatic mNET progression was recog-
nized [18, 19, 24, 25].
4. Discussion
Overall, the available studies demonstrate eﬀective and safe
use of radioembolization for liver dominant disease in
mNET. There is a positive eﬀect on symptoms, quality of
life, response criteria, and survival in various stages of
progression, which is mirrored in the recommendations
of the Radioembolization Brachytherapy Oncology Consor-
tium [26]. A robust safety proﬁle for radioembolization with
Yttrium-90 microspheres was conﬁrmed in two 2009 analy-
ses [26, 27]. The overall incidence of RILD, in particular, was
estimated to be 0.8% [26].
Evidence-based data for treatment decisions in inoper-
able mNET are not presently available. A recent overview
of strategies for advanced enteropancreatic NET compre-
hensively presents the panorama of current and developing
multimodal treatment options. In general, former wait-
andsee strategies even in well-diﬀerentiated tumors with
m i n o r - t o - m o d e r a t et u m o rl o a d sw i l lh a v et ob er e e v a l u a t e d ,
as tumor progression, with median TTP of 6 months, is
inevitable [5].
In order to relieve the common carcinoid syndrome con-
sisting of diarrhea, ﬂushing, hypertension, bronchocon-
striction, right valvular heart failure and other endocrine
eﬀects, or eﬀect medication sparing, at least palliative tumorInternational Journal of Hepatology 3
Table 1: Study outcomes of TARE for NET liver metastases.
Lead Author, Year n Prospective? Treatment Phase ORR SD Symptom
Response Survival
Arslan, 2011 [17] 10 No ? 80% 10% NR All alive at 4–28mo
Cao, 2010 [15] 51 No ? 38% 27% NR 36mo
Saxena, 2010 [26] 48 No ? 55% 23% NR 35mo
Kalinowski, 2009 [19] 9 Yes Refractory 66% 33% Improved QoL 57% alive at 36mo
Kennedy, 2009 [27] 148 No Refractory/salvage 63.2% 22.7% NR 70mo
King, 2008 [22] 34 Yes First-line∗ 50% 14.7% 50% 59% alive at 37 ±
2mo
Murthy, 2008 [16] 8 No Refractory/salvage 12.5% 50% NR 14mo














Meranze, 2007 [24] 10 Yes First-line 40% 60% Improved QoL 70% alive at 35mo
McGrath, 2007 [25] 26 No First-line/refractory 58.3% 33% NR 69% alive at 17.3mo
Kennedy, 2006 [21] 18 No First-line/refractory 89% NR NR 89% alive at 27mo
∗combined with 5-FU.
∗∗with Yttrium-90 glass microspheres, all others with Yttrium-90 resin microspheres. Median survival in last column unless otherwise indicated. ORR:
objective response rate (complete + partial response). SD: stable disease. NR: not reported. QoL: quality of life.
debulking, either surgically or with transarterial approaches,
is necessary. Hepatic tumor burden debulking appears to
i m p r o v es u r v i v a la sw e l l[ 28–32]. 5-year survival rates for
mNET are 50–59% according to national cancer registries
[33, 34]. With intervention, 5-year survival reaches 72–100%
in limited hepatic spread and 25–51% in more extensive
hepatic spread [35, 36].
TARE (see Table 1) is at least comparable to TA(C)E in
eﬀectiveness [13, 14]. An advantage of the TARE protocol
is the generally single treatment to achieve this eﬀect, while
TA(C)E is generally applied multiple times. This obvious
patient comfort and quality of life advantage is compounded
by the well-known lower severity of the “postembolization”
syndrome (which in TARE’s case represents radiation irri-
tation) and reduced need for inpatient admittance. On the
other hand, preparatory angiography mapping, emboliza-
tion, and treatment simulation are a necessary ﬁrst step in
TARE workup.
It is conceivable that Yttrium-90 microspheres can be
held in reserve, so to speak, for further repeated use to
establish prolonged disease control. In this respect, it seems
superior to repeated TA(C)E. For one thing further extended
use of TA(C)E is limited by the sheer number of necessary
repetitions, reducing patient days outside the hospital and
thus quality of life. The extended use of TARE, on the other
hand, would likely not reach the number of regular TA(C)E
sessions. Similar advantages also apply to side eﬀects and
outpatient ﬂexibility. Also, the degree of embolic eﬀect could
skew repeated treatment schemes to TARE’s favor: while
TA(C)E may “prune” the arterial tree to such an extent that
agent delivery is impaired due to the larger particle size
(100–300µmv e r s u s3 5 µm for TARE), the lesser embolic
eﬀect of TARE may keep the path to the tumor more
reliably open. Further examination of the limits of dose and
repeat application with regard to RILD could possibly enable
attempts at treating even more advanced hepatic spread with
radioembolization. An investigation of radiosensitizers, for
example, capecitabine, to be concurrently used with TARE
may also be warranted as this could represent another lever
to further potentiate its eﬀects [37].
Apparently disease control through radioembolization
treatment is eﬀective and long-lasting enough for most pa-
tients in the observed time spans to succumb to pro-
gressive extrahepatic disease. Thus, initiation/resumption of
chemotherapy, possibly combined with extrahepatic local
resection/ablation if necessary, appears reasonable.
Further considerations concern the endpoints surveyed
in Yttrium-90 treatment studies. Morphologic response
criteria(i.e.,RECIST)maybemisleadinginTAREfollowups.
Since the RECIST criteria were designed to reﬂect the
response to systemic chemotherapy, the response to TARE
is not gradual shrinkage but the creation of a necrotic
tumor whose margins may not be well circumscribed in
the baseline CT yielding a reading of progressive disease or
mere stable disease. Collection of tumor marker data, for
example, Chromogranin A, as well as functional parameters,
for example, PET, may help to overcome some of these
shortcomings. Emphasis should also be laid on formal
measurements of quality of life in subsequent studies of
TARE to better gauge this essential patient dimension.
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